TENEX Drug Patent Profile

When do Tenex patents expire, and what generic alternatives are available?

Tenex is a drug marketed by Promius Pharma and is included in one NDA.

The generic ingredient in TENEX is guanfacine hydrochloride. There are seven drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the guanfacine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenex

A generic version of TENEX was approved as guanfacine hydrochloride by WATSON LABS on October 17^th, 1995.

Summary for TENEX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TENEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-001	Oct 27, 1986		DISCN	Yes	No
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-002	Nov 7, 1988		DISCN	Yes	No
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-003	Nov 7, 1988		DISCN	No	No

International Patents for TENEX

See the table below for patents covering TENEX around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	959860	ACETYL-GUANIDINE DERIVATIVES ACETYL-GUANIDINE DERIVATIVES
Yugoslavia	222968
Netherlands	141783

Investment scenario and fundamentals analysis for TENEX (Clonidine)

Last updated: February 10, 2026

Overview

TENEX is a brand of clonidine, an alpha-2 adrenergic agonist primarily prescribed for hypertension management. Market demographics, competitive landscape, regulatory environment, and patent status influence its investment outlook.

Market Landscape

Clonidine, marketed as TENEX and generics, addresses hypertension, ADHD, opioid withdrawal, and certain pain conditions. The global antihypertensive market is valued at approximately $57 billion in 2022, with clonidine representing a smaller segment due to its age and generic availability.

Usage has declined in developed markets owing to the advent of newer antihypertensive agents, but clonidine retains niche applications, especially in specific patient populations.

Revenue and Market Share

• Blockbuster threshold: Not applicable; TENEX and clonidine generics generate modest revenue. The drug’s contribution to Eli Lilly’s portfolio, the current patent holder, is estimated at $10–$15 million annually.
• Generic penetration: 80-90% in the U.S., reducing profitability. The patent expired in 2018, increasing generic competition.

Patent and Regulatory Status

• Original patent deeds for TENEX expired in 2018.
• FDA approval was first granted in 1974.
• Current formulations are off-patent; no proprietary exclusivity remains.
• No recent regulatory hurdles; existing approvals remain valid.

Competitive Dynamics

• Generics: Dominant market share due to low barriers to entry and patent expiration.
• Brand Differentiation: Limited; TENEX mainly competes via brand trust, but generics dominate.
• Alternative treatments: Newer antihypertensives and non-pharmacologic interventions reduce reliance on clonidine.

R&D and Pipeline

• No active clinical development programs targeting TENEX specifically.
• The broader clonidine class has no significant new formulations or indications under development.

Financials and Investment Outlook

• Patent expiry impact: Revenue from TENEX has declined over recent years.
• Pricing pressure: Continues due to generic competition lowering margins.
• Market growth: Limited; potential slight uptick if used for emerging indications or combination therapies, though currently minimal.

Risks and Opportunities

• Risks:

  • Further generic price erosion.
  • Market decline due to newer drugs.
  • Regulatory or safety concerns, though none are currently reported.

• Opportunities:

  • Repurposing for new indications; limited pipelines diminish this prospect.
  • Positioning within niche markets like opioid withdrawal, if clinical evidence supports expansion.

Investment Thesis

TENEX represents a low-growth, mature asset with diminishing revenues and margins due to patent expiration and generics. Investment potential is minimal unless tied to strategic acqusitions or pipeline developments within Eli Lilly.

Key Takeaways

• The drug's original patent has expired; generics dominate.
• Market share continues to decline due to competition from newer agents.
• No active pipeline or new formulations reduce upside potential.
• Revenue impact is marginal for Eli Lilly’s overall portfolio.
• Risks from pricing pressures and market saturation are high.

FAQs

Q1: Is TENEX a viable investment for high returns?
No. The drug faces patent expiration and fierce generic competition, limiting growth.

Q2: Are there new indications or formulations under development?
No significant developments are underway for TENEX or clonidine.

Q3: How does patent expiry affect TENEX?
Patent expiry in 2018 led to generic entry, significantly reducing the drug’s revenues.

Q4: What are the prospects for market expansion?
Limited. Current uses are well-established and declining; no new markets appear imminent.

Q5: Should investors consider TENEX as part of a diversified healthcare portfolio?
Given its mature status and limited upside, it should not be a core holding for growth-focused investors.

Sources

1. IBISWorld, "Antihypertensive Drugs Market," 2022.
2. Eli Lilly, Annual Report 2022.
3. FDA, Drug Approvals and Patent Data, 2018.
4. EvaluatePharma, "Pharmaceutical Market Analysis," 2022.
5. MarketWatch, "Generic Drug Market Trends," 2022.